Syngene International Ltd. AI Stock Analysis
Want to see IN:SYNGENE full AI Analyst Report?
Syngene International Ltd. (SYNGENE) AI Stock Analysis
Syngene International Ltd.
(NSE:SYNGENE)
The score is supported primarily by a strong balance sheet and historical revenue growth, with additional support from generally constructive technical indicators. Recent profitability and cash-flow concerns, combined with a high P/E and low dividend yield, materially constrain the overall score.
Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 148.36B
- Dividend Yield
- 0.28%
- Average Volume (3M)
- 147.69K
- Price to Earnings (P/E)
- 97.6
- Beta (1Y)
- 0.90
- Revenue Growth
- -5.99%
- EPS Growth
- -60.30%
- Country
- India
- Employees
- 6,692
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Syngene International Ltd. Business Overview & Revenue Model
Company Description
Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The c...
Syngene International Ltd. Financial Statement Overview
Summary
Strong balance-sheet quality and long-term revenue growth support the score, but FY2026 margin compression, lower return on equity, and volatile free cash flow reduce financial strength.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
65Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.22B | 37.39B | 36.42B | 34.89B | 31.93B | 26.04B |
| Gross Profit | 11.39B | 12.62B | 24.41B | 23.50B | 21.56B | 17.12B |
| EBITDA | 8.23B | 9.13B | 10.47B | 10.73B | 9.84B | 7.43B |
| Net Income | 1.86B | 3.17B | 4.96B | 5.10B | 4.64B | 3.96B |
Balance Sheet | ||||||
| Total Assets | 66.58B | 70.55B | 67.96B | 61.52B | 58.31B | 55.64B |
| Cash, Cash Equivalents and Short-Term Investments | 5.30B | 12.89B | 13.97B | 10.77B | 13.54B | 12.81B |
| Total Debt | 5.07B | 4.58B | 5.78B | 5.55B | 8.15B | 10.22B |
| Total Liabilities | 18.00B | 22.16B | 20.69B | 18.94B | 22.13B | 22.66B |
| Stockholders Equity | 48.59B | 48.39B | 47.27B | 42.58B | 36.18B | 32.98B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 6.11B | 3.98B | 5.50B | 3.05B | 1.05B |
| Operating Cash Flow | 0 | 9.55B | 11.68B | 10.42B | 8.38B | 5.81B |
| Investing Cash Flow | 0 | -9.11B | -7.45B | -4.96B | -6.88B | -6.12B |
| Financing Cash Flow | 0 | -2.04B | -1.42B | -5.51B | -3.40B | -313.00M |
Syngene International Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Positive. The current price of 451.85 is above the 20-day moving average (MA) of 417.24, above the 50-day MA of 391.97, and above the 200-day MA of 418.35, indicating a bullish trend. The MACD of 16.24 indicates Negative momentum. The RSI at 68.01 is Neutral, neither overbought nor oversold. The STOCH value of 70.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SYNGENE.
Syngene International Ltd. Peers Comparison
Overall Rating
IN:ANTHEM73Outperform
IN:SYNGENE67Neutral
IN:CONCORDBIO57Neutral
IN:DCAL55Neutral
IN:BIOCON47Neutral
IN:PANACEABIO46.9Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 528.58B | 87.17 | ― | 0.21% | -1.20% | 18.53% | |
| 67Neutral | INR 176.65B | 97.56 | ― | 0.28% | -5.99% | -60.30% | |
| 57Neutral | INR 116.38B | 40.65 | ― | 1.38% | 4.02% | -12.81% | |
| 55Neutral | INR 18.59B | 26.57 | ― | ― | -0.11% | -184.93% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | INR 589.95B | 121.87 | ― | 0.14% | 5.70% | -24.72% | |
| 47Neutral | INR 21.64B | 111.61 | ― | ― | 19.43% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SYNGENE | Syngene International Ltd. | 451.85 | -186.19 | -29.18% | |
| IN:BIOCON | Biocon Limited | 366.00 | -28.18 | -7.15% | |
| IN:CONCORDBIO | Concord Biotech Ltd. | 548.40 | -152.83 | -21.79% | |
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 115.85 | -116.25 | -50.09% | |
| IN:PANACEABIO | Panacea Biotec Limited | 336.25 | -12.30 | -3.53% | |
| IN:ANTHEM | Anthem Biosciences Limited | 950.95 | 320.84 | 50.92% |
Syngene International Ltd. Corporate Events
Syngene posts Q2 FY27 earnings call audio for investors
Syngene International Limited has notified the Indian stock exchanges that the audio recording of its Q2 FY27 post-earnings call held on October 28, 2026 has been uploaded to the company’s website. The disclosure has been made under Regulation 30 of...
Syngene Publishes Investor Presentation for September 2026 Period
Syngene International Ltd. has released an investor presentation for the quarter and half year ended September 30, 2026, in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015. The document, intended fo...
Syngene Announces Resignation of Corporate Affairs Head
Syngene International Ltd. has announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and a member of the Executive Committee, effective at the close of business on September 21, 2026. The company has notified the B...
Syngene Schedules Analyst Meet at Kotak Healthcare Forum 2026
Syngene International Ltd. has scheduled a meeting with analysts and institutional investors at the Healthcare Forum 2026 organized by Kotak in Mumbai on September 17, 2026. The engagement will take place as a physical group and one-on-one investor c...
Syngene Grants 1.43 Million Performance Share Units Under 2023 Long-Term Incentive Plan
Syngene International has granted 1,426,061 Performance Share Units (PSUs) to eligible employees under its Long Term Incentive Performance Share Plan 2023, following approval by the company’s Nomination and Remuneration Committee. The grant, aligned...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
